Patient Monitoring Market Size is Projected to Reach USD 112.47 Billion by 2033, Growing at a CAGR of 7.3%: Straits Research
The global patient monitoring market size was valued at USD 55.60 billion in 2024 and is projected to reach from USD 59.66 billion in 2025 to USD 112.47 billion by 2033, growing at a CAGR of 7.3% during the forecast period (2025-2033).
New York, United States, Jan. 27, 2025 (GLOBE NEWSWIRE) -- A set of instruments known as a patient monitoring system enables medical professionals to monitor a patient's health. These gadgets—remote physiologic monitoring—are routinely used for remote patient monitoring. Utilizing digital technology, they gather and track patient health data, transmit it electronically to healthcare specialists, and use it to aid in condition evaluation, diagnosis, and treatment. This technology alters how healthcare is delivered in the US by reducing costs and improving patient outcomes. Patient monitoring systems are easier to define in terms of their uses.
One well-known example of a patient monitoring system is electrocardiography (ECG), which records the heart's electrical activity. Hypertensive patients use monitoring tools to keep an eye on their blood pressure. People with diabetes utilize glucose monitoring equipment to assess blood glucose levels and prevent potentially dangerous consequences. Patients with chronic obstructive pulmonary disease (COPD), asthma, and other respiratory conditions also require monitoring equipment.
Download Free Sample Report PDF @ https://straitsresearch.com/report/patient-monitoring-market/request-sample
Market Dynamics
Growing Adoption of Remote Patient Monitoring Drives the Global Market
Recent years have seen a significant increase in the usage of patient monitoring devices for continuous vital sign monitoring and analysis, particularly during the COVID-19 outbreak. Patient monitoring systems enable medical personnel to monitor patients' health remotely or at home. Healthcare can become more digitalized to lower costs and boost revenue for medical practices. Additionally, remote monitoring equipment that provided medical treatment in a comfortable setting and permitted remote monitoring from patients' homes was helpful for non-COVID-19 patients who needed chronic care. This increased the number of beds and other important clinical resources available in hospitals and other healthcare facilities for patients who required immediate on-site care.
Due to stringent government regulations and favorable laws for patient monitoring equipment, it is anticipated that many organizations will be motivated to develop novel pharmaceuticals for treating chronic diseases like cardiovascular and respiratory diseases, cancers, diabetes, and chronic respiratory diseases. The widespread use of patient monitoring tools in clinical research trials and the convenience of monitoring is made possible by the market penetration of these tools, which hastens the development of novel medications. The increased prevalence of chronic diseases directly impacts the utilization of ICUs. Due to the benefits offered by patient monitoring devices, such as shorter hospital stays, fewer adverse effects, and speedier recovery times, the market is predicted to grow profitably.
Rising Demand in Non-Hospital Creates Tremendous Opportunities
The sustainability of the current healthcare system is a serious worry for governments worldwide. Due to escalating healthcare expenditures, particularly in hospital settings, the focus has recently switched to alternative treatment modalities, including home healthcare. In addition, the frequency of hospital readmissions has dramatically decreased since the introduction of remote and home monitoring technology. There is consequently a growing demand for effective home medical devices, such as fetal and neonatal monitors, ECG recorders, temperature monitors, pulse oximeters, and event monitors.
Regional Analysis
North America is the most significant patient monitoring market shareholder and is estimated to exhibit a CAGR of 8.1% over the forecast period. 42.7% of the market for patient monitoring devices was in North America. This results from several things: its well-established healthcare infrastructure, high healthcare spending, monopolistic market participants, and the rapid adoption of cutting-edge technologies. North America has the most developed medical equipment market worldwide. The market is anticipated to be driven by the quick adoption of patient monitoring and homecare devices for routine, continuous, and long-term patient monitoring and reducing the number of hospital visits during the projected period.
Additionally, favorable payment terms are expected to accelerate market expansion. Additional factors anticipated to drive market expansion include the rise in accidents, sports injuries, and health problems associated with lifestyle. Increased emergency care needs and increased usage of mobile surgery centers are expected to drive the market during the forecasted period.
Europe is anticipated to exhibit a CAGR of 8.4% over the forecast period. Europe accounted for 25.1% of the global market for patient monitoring devices in 2020. Europe's market includes countries including Germany, France, Italy, Spain, and the United Kingdom. The increasing demand for patient monitoring devices and central data management systems for accurate information and medical services is expected to boost the market. Market expansion is fueled by the prevalence of diseases and the growing older population. In 2020, more than one-fifth of people in Europe were over 65.
In Europe, the leading cause of illness and mortality is chronic disease. The requirement for patient monitoring devices has increased due to the number of patients admitted to healthcare facilities. The COVID-19 pandemic has increased the usage of patient monitoring devices and remote monitoring to assess and analyze vital signs in healthcare settings. To obtain more exact and accurate results economically, advanced patient monitoring devices are constantly being developed and presented by various market participants. As a result, the market for patient monitoring devices is anticipated to grow during the period in question.
Ask for Customization @ https://straitsresearch.com/report/patient-monitoring-market/request-sample
Key Highlights
The global patient monitoring market size was valued at USD 55.60 billion in 2024 and is projected to reach from USD 59.66 billion in 2025 to USD 112.47 billion by 2033, growing at a CAGR of 7.3% during the forecast period (2025-2033).
Based on the product, the global patient monitoring market is bifurcated into blood glucose monitoring systems, cardiac monitoring devices, multiparameter monitoring devices, respiratory monitoring devices, temperature monitoring devices, hemodynamic/pressure monitoring devices, fetal neonatal monitoring devices, neuromonitoring devices, weight monitoring devices, other. The blood glucose segment dominates the global market and is projected to exhibit a CAGR of 9.1% over the forecast period.
Based on end-users, the global patient monitoring market is divided into Hospitals, Ambulatory Surgery Centers, Home Care Settings, and Others. The hospital segment is the most significant contributor to the market and is estimated to exhibit a CAGR of 8.2% over the forecast period.
North America is the most significant global patient monitoring market shareholder and is estimated to exhibit a CAGR of 8.1% over the forecast period.
Competitive Players
Abbott
Boston Scientific
Medtronic
Philips
Nihon Kohden Health Anywhere Inc.
Koninklijke Philips N.V.
G.E. Healthcare
MASIMO CORPORATION
Smiths Medical
Bosch
Biotronik
Intel
Welch Allyn
Recent Developments
In June 2023, With the introduction of its Generation (Gen) 1 device, medical diagnostic company Know Labs provides the first non-invasive glucose monitor. The Generation (Gen) 1 gadget prototype uses radio waves and machine learning algorithms to measure blood sugar levels through the skin.
In May 2023, Royal Philips, a global leader in health technology, and Masimo, a global medical technology company, announced FDA clearance for SedLine® Brain Function Monitoring, Regional Oximetry (O3®), and CO2 measurements in Philips Patient Monitors – IntelliVue MX750 and MX850. The latest extension will let clinicians make quick and informed judgments without additional monitoring equipment.
Segmentation
By Product
Blood Glucose Monitoring Systems
Cardiac Monitoring Devices
Multiparameter Monitoring Devices
Respiratory Monitoring Devices
Temperature Monitoring Devices
Hemodynamic/Pressure Monitoring Devices
Fetal and Neonatal Monitoring Devices
Neuromonitoring Devices
Weight Monitoring Devices
By End-User
Hospitals
Ambulatory Surgery Centers
Home Care Settings
By Region
North America
Europe
Asia-Pacific
Latin America
The Middle East and Africa
Get Detailed Market Segmentation @ https://straitsresearch.com/report/patient-monitoring-market/segmentation
About Straits Research Pvt. Ltd.
Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.
Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client's purchase. We overcome our clients' issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.
Phone: +1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
Email: sales@straitsresearch.com
Follow Us: LinkedIn | Facebook | Instagram | Twitter
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Amid cost pressures, US employers are shifting their benefit strategy, WTW survey finds
More companies expanding choice, tackling high cost and reallocating benefit spend NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- As U.S. employers grapple with heightened economic uncertainty and greater financial pressures on budgets, steering the right course on benefit strategy is more challenging than ever. This is according to a survey by WTW (NASDAQ: WTW), a leading global advisory, broking and solutions company. As a result, companies are turning to smarter spending, sharper focus and using benefits as a strategic tool to drive engagement, retention and purpose. The 2025 Benefits Trends Survey found rising benefit costs to be the top issue (90%) influencing U.S. employers' benefit strategies in 2025, up from 67% in 2023. Other top concerns include competition for talent (52%), expectations for an enhanced employee experience (43%), cost of living (39%) and rising mental health issues (32%). 'After a long period of high benefits inflation and in the face of a possibly weakening economy, employers are taking a step back and looking to focus on what drives real value for employees and the business. That means targeting support and spending on the benefits that matter most, enabling personalization and helping employees make better decisions,' said Jeff Levin-Scherz, Population Health Leader, North America, Health & Benefits. As the cost of medical care continues to show double digit growth in the U.S., employers face greater challenges in delivering their strategy in key areas such as health benefits (44%), wellbeing programs (44%), and leave benefits (36%). To address these concerns, employers are shifting their strategy. Few are expanding their benefit portfolio, choosing to instead focus on extracting value from their current offerings and improve financing, employee experience, analytics and administration. Compared to just 8% in the past year, 63% of employers plan to reallocate or rebalance spend in the next three years. A majority (73%) plan to tackle high costs by enhancing value or switch to better-value vendors across health, retirement and risk benefits. Just under half (44%) plan to tackle high-cost medical conditions and 37% plan to adopt a network of preferred medical providers. Eager to address employee pressure points, companies are also looking to improve the following priority areas over the next three years: maximizing value, mental health, health benefits, financial wellbeing and family support. Many plan to increase their use of communication and use nudges and navigation solutions to influence behaviors and enhance the employee experience. Regularly reviewing vendor performance, including employee feedback, is also a key action employers are taking. 'Organizations are facing more pressure than ever to deliver the right benefits strategy. Finding innovative solutions for old and new challenges and reallocating spend on benefits that deliver true value is a good start. There is still a long way to go to address these pressure points, but employers are headed in the right direction by focusing on what matters most to their employees,' said Levin-Scherz. About the survey The 2025 Benefit Trends Survey was conducted from early March to mid-April. Respondents include 696 U.S. employers, representing a broad range of industries in both the private and public sector. About WTW At WTW (NASDAQ: WTW), we provide data-driven, insight-led solutions in the areas of people, risk and capital. Leveraging the global view and local expertise of our colleagues serving 140 countries and markets, we help organizations sharpen their strategy, enhance organizational resilience, motivate their workforce and maximize performance. Working shoulder to shoulder with our clients, we uncover opportunities for sustainable success—and provide perspective that moves you. Media contactIleana Feoli: +1 212 309
Scientific American
22 minutes ago
- Scientific American
Can You Still Get a COVID Vaccine This Fall? Here's What to Know
For the first time since the COVID vaccines became available in pharmacies in 2021, the average person in the U.S. can't count on getting a free annual shot against a disease that has been the main or a contributing cause of death for more than 1.2 million people around the country, including nearly 12,000 to date this year. 'COVID's not done with us,' says Jennifer Nuzzo, an epidemiologist at Brown University. 'We have to keep using the tools that we have. It's not like we get to forget about COVID.' In recent weeks, the Department of Health and Human Services, led by prominent antivaccine activist Robert F. Kennedy, Jr., has announced a barrage of measures that are likely to reduce COVID vaccine access, leading to a swirl of confusion about what will be available for the 2025–2026 season. HHS officials did not respond to a request for comment for this article. On supporting science journalism If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today. Government officials appear to be limiting COVID shots to people who are aged 65 and older and to those who have certain preexisting health conditions—groups that have long been known to face a higher risk of developing severe COVID. Pregnant people and some children, meanwhile, appear to be explicitly excluded from access, despite plentiful evidence that vaccines are very safe and effective for them and that COVID infections can cause them significant harm. Scientific American spoke with clinicians and public health experts about the latest COVID vaccine recommendations, what access may look like this fall and how these policies might influence people's vaccination choices and health. What COVID vaccines will be manufactured this year? Public health experts are monitoring a strain of the COVID-causing virus SARS-CoV-2 called NB.1.8.1, which was first detected early this year and last month became responsible for one in 10 COVID cases globally. So far, the new variant has mostly been reported in Asia and Europe. But it has also been picked up in airport surveillance in multiple U.S. states, says Peter Chin-Hong, an infectious disease physician and a professor of medicine at the University of California, San Francisco. The emergence of a new variant isn't surprising, particularly at this time of year, Chin-Hong says. 'It's kind of acting like clockwork—maybe this might be the variant of the summer,' he adds. Still, NB.1.8.1 has led to concerns about a potential surge in cases—although Chin-Hong and other scientists don't have any evidence so far that it causes more serious disease than other currently circulating strains. 'All of these new variants, they might be more transmissible, they might be more immune evasive, but I've seen no data whatsoever that suggests that they're more pathogenic,' says Angela Rasmussen, a virologist at the University of Saskatchewan. Within the U.S., a strain called LP.8.1 has been the most common one detected since March. Both NB.1.8.1 and LP.8.1 are among the alphabet soup of strains that descended from a key ancestor lineage called Omicron JN.1, which dominated U.S. cases by early 2024. Current vaccines target this category of strains. And in May a Food and Drug Administration panel determined that, this year, vaccine producers should again tailor their shots to a single strain within the JN.1 lineage—preferably LP.8.1. What's going on with COVID vaccine policy? Strain selection aside, the recent messaging and decision-making on vaccine policy for COVID and beyond have been chaotic, with various governmental groups and officials announcing different access guidelines and restrictions. 'The situation we're in right now is nuts,' says Nuzzo, referring to the fact that agency leaders have sidestepped the formal science committees that traditionally make vaccine-related decisions. 'We don't change vaccine policy on a willy-nilly basis. There's an incredible amount of nuance, and all of the data need to be considered.' But on June 9 Kennedy took a major step against this evidence-driven decision-making process by firing the entire CDC Advisory Committee on Immunization Practices (ACIP). Kennedy announced the committee rehaul in a Wall Street Journal op-ed, in which he alleged there were 'persistent conflicts of interest' among committee members. According to a recent HHS statement, new committee members are under consideration, and the group will still meet as scheduled from June 25 to 27. ACIP has traditionally been particularly important because any vaccine it recommends must be fully paid for by health insurance companies—a condition that greatly determines real-world access. It's unclear what the committee's overhaul will mean for COVID vaccine access in particular. Another concern is that Kennedy announced in late April that HHS would implement a policy requiring all 'new' vaccines—including updated versions of existing ones, such as COVID shots—to be tested against a placebo. The original COVID vaccines were tested in just this manner. But conducting similar tests when an effective and very safe vaccine already exists would be not only unethical for researchers but also expensive and time-consuming for manufacturers. It remains unclear when the new policy will take effect. What does this mean for COVID vaccine access this fall? If you are 65 years old or older, you should be able to get a COVID shot as you have in recent years. If you have an underlying condition such as cancer, diabetes, or heart or lung problems, you may also be able to get a COVID shot as usual. These issues and several others are on the CDC's list of conditions that leave people more vulnerable to severe disease, and this list is included in the description of the new regulatory framework. One 2021 study looked at many (but not all) of the conditions on the list and estimated that three in four U.S. adults has at least one. People are allowed to self-disclose a preexisting condition at pharmacies without a prescription or doctor's note. That list could also be expanded later if new research finds other risk factors that increase people's risk of severe COVID, says Jacinda Abdul-Mutakabbir, a clinical pharmacist and an assistant professor at the University of California, San Diego. But there's also a chance that qualifying conditions may be reduced instead. For example, current or recent pregnancy is included in the CDC's existing list, but HHS officials announced in late May that the COVID vaccine would no longer be recommended for pregnant people. Data have shown that COVID may cause various complications during pregnancy —increasing the risk that the pregnant person may require emergency care, be put on a ventilator or die. The newborn child of an infected person is also more likely to be born preterm or to have low birth weight. And babies younger than six months old—who are ineligible for vaccination because of their immature immune system—have the highest rates COVID hospitalization after adults aged 75 and older. In contrast, evidence from people vaccinated during pregnancy show that newborns receive protective immunity through antibodies that cross the placenta and are found in breast milk, Chin-Hong explains. Healthy children also face new restrictions to COVID vaccine access: The shot is now only recommended to them based on 'shared clinical decision-making,' according to the vaccine schedules released by the CDC last month. This means parents must consult with a health practitioner about whether to vaccinate such children. Experts worry about the consequences of restricting access for kids. Children under age 18 make up a smaller percentage of COVID hospitalizations and deaths. But that doesn't mean zero risk, Chin-Hong says. 'We know that COVID still kills kids,' he says. 'No death of a child is a good death—and these are all preventable.' 'Because children and pregnant people are considered vulnerable populations, they were not included in the original studies that were done for the COVID vaccines,' Abdul-Mutakabbir says. But five years' worth of real-world vaccine data from these groups show the health benefits. 'We do see effectiveness and safety in these vaccines,' she says. It's still possible that the late June ACIP meeting will shift the landscape again. But if you want a COVID vaccine this fall and don't meet current guidelines, you may still be able to request a shot. Your insurance may not pay for it, however, leaving you to risk a price tag of around $200. 'Insurance companies or providers are only required to pay for vaccines that are listed as recommended by the CDC,' Abdul-Mutakabbir says. Full, partial or no-cost coverage for nonrecommended vaccines is at the insurance provider's discretion. Any changes to coverage—and the times at which those changes are announced—will vary among programs, including private and governmental ones, such as the federal-state program Medicaid and the federal program Medicare. Until then, Chin-Hong and Abdul-Mutakabbir say, the COVID vaccines released in the fall of 2024 are still recommended and available to people who haven't already had one. And as of April 26, only 23 percent of adults and 13 percent of children in the U.S. had received the shot. 'If you are nervous about the surge or planning summer travel, I would recommend' getting the vaccine, Abdul-Mutakabbir says. The larger fight over vaccines For Rasmussen, the confusion over COVID shots signals the beginning of a longer tug-of-war—with Kennedy's HHS on one end. 'I think I know what their plan is, and it's to reduce access to vaccines in general,' she says. 'In my view, this is an incremental step in a larger attack on vaccination in general.' She encourages people worried about vaccine restrictions—and about the role of science in making these decisions—to call their congressional legislators. 'A lot of people speaking out is what is needed right now to make a big difference here,' she says. Abdul-Mutakabbir also hopes people continue to seek vaccines for COVID and other diseases—especially while they are still easily available. 'It's important that we consider the things that we can protect ourselves against,' Abdul-Mutakabbir says. 'Should you have a barrier with getting a COVID vaccine, guess what? There's no change to the flu vaccine; there's no changes to the pneumococcal recommendations; there's no change to measles, mumps, rubella vaccine. Get the vaccines that we can get.'
Yahoo
30 minutes ago
- Yahoo
Minnesota Health Market Review 2025: HMOs Suffer $1 Billion Revenue Loss as Enrollment Drops
HMO profitability plunged in 2024, with enrollee numbers dropping by 168,000. Medicaid managed care plans saw significant losses, with premium revenues declining by over $1 billion. However, Medicare Advantage plans grew by 8.7%. Part One of the 2025 Minnesota Health Market Review details these shifts, with Part Two focusing on hospital systems. Dublin, June 10, 2025 (GLOBE NEWSWIRE) -- The "Minnesota Health Market Review 2025 (Part 1)" report has been added to offering. HMO profitability plunged in 2024, as HMOs and County-Based Purchasing plans reported lower revenues, higher medical expenses and large losses on operations. The number of enrollees in Medicaid managed care plans dropped by about 207,000 in 2023 and 2024, although it is still higher than before the COVID-19 pandemic. The analyst reports on these and other findings in Part One of Minnesota Health Market Review 2025. This is the 36th edition of the report, which was first published in 1990. The new report finds that: Total enrollment in HMOs and County-Based Purchasing (CBP) plans dropped by 168,000 or 9.7% in 2024. While membership in Medicare Advantage plans grew by 8.7%, enrollment in Medicaid and other state programs decreased by 15%, as the state completed re-evaluating the eligibility of Medicaid recipients. As enrollment dropped, premium revenues for HMOs dropped by more than $1 billion, or 6.5%. However, their medical costs increased, and they had combined underwriting losses of $1.067 billion. UCare had the largest underwriting losses at $606.5 million, followed by HealthPartners ($170.9 million) and Medica Health Plans ($154.3 million). Hennepin Health had underwriting losses of $56.2 million. Most of the losses were in two key lines of business: Medicaid and other public programs and Medicare Advantage. HMOs and county plans lost $640.4 million on Medicaid plans in 2024 after reporting underwriting profits of $367.8 million in 2023 and $726.5 million in 2022, their best results ever. Even with the large losses in 2024, Medicaid plans have posted underwriting income of $939.5 million in the last 10 years. That includes the results for Minnesota Senior Health Options, a managed care program for beneficiaries of both Medicare and Medicaid, where the health plans have reported combined underwriting income of $720.3 million in the last nine years. Enrollment in Medicare Advantage plans has grown steadily since 2016, but they have not been profitable in Minnesota since 2022. In 2024, UCare lost $266.7 million on its Medicare Advantage plans, including $102.3 million in reserves set aside in anticipation of future revenue shortfalls. It already spent $47 million from that reserve in the first quarter of 2025 but still lost $25.5 million. Other health plans reported improved results in the first three months of 2025. Data from 2023 show that 96% of Minnesotans have health insurance, but that is likely to drop sharply if the budget bill passed by the U.S. House of Representatives is enacted. Cuts to Medicaid are projected to result in about 253,000 Minnesotans losing Medicaid benefits. Changes to subsidies sold on the MNsure exchange, where individual enrollment has grown to 167,000, will likely result in thousands losing coverage. Key Topics Covered: Introduction Market Structure Health Plan Companies Network Arrangements and Provider Systems Trend Analysis Health Plan Enrollment Individual Markets and MNsure State Health Care Programs Medicare Health Plans Health Plan Profitability Financial Results by Line of Business Health Plan Capital A Look Ahead For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
